Xin Kaiyuan and Subsidiary Heer Medical to Jointly Invest RMB 50 Million in Huadao Biopharma

Gelonghui September 19thNew Open Source(300109.SZ) announced that, in order to further enhance the company's competitive advantage in the field of precision medicine, the company and its subsidiary Wuhan Heer MEDICAL Technology Development Co., Ltd. (hereinafter referred to as "Heer Medical") plan to sign the "D+2 Round Investment Agreement of HuaDao CAR-Tcell" with HuaDao CAR-Tcell and its 28 shareholders. According to the agreement, the company and its subsidiary Heer Medical will invest RMB 30 million and RMB 20 million respectively in HuaDao CAR-Tcell through capital increase. After the completion of this capital increase, the company and its subsidiary Heer Medical will hold 12.2150% and 0.7168% of HuaDao CAR-Tcell's equity respectively.